• Anti-b Suppresses mTOR Pathways to Treat Hyperlipidaemia

  2026-05-10

  This study identifies Anti-b as a novel small molecule that reduces hyperlipidaemia and hepatic steatosis in rodent models by targeting mTOR/PPARγ and mTOR/SREBP1 signaling. The research offers mechanistic clarity and highlights mTOR pathway modulation as a promising strategy for metabolic disease intervention.

• NMDA (N-Methyl-D-aspartic acid) in Neurodegenerative Disease

  2026-05-09

  NMDA (N-Methyl-D-aspartic acid) stands out as a gold-standard tool for modeling excitotoxicity and oxidative stress in neurodegenerative research. By enabling highly controlled calcium influx and receptor-specific signaling, APExBIO’s NMDA empowers reproducible, translationally relevant experiments from glaucoma to stem cell-based assays.

• Cell Counting Kit-8 Plus: Optimizing Tetrazolium Salt Assays

  2026-05-09

  The Cell Counting Kit-8 (CCK-8) Plus from APExBIO elevates cell proliferation and cytotoxicity assays with enhanced sensitivity, speed, and reproducibility. This guide details actionable protocol upgrades, troubleshooting tips, and evidence-backed workflows—empowering researchers to streamline drug discovery and inflammation studies using the latest WST-8 tetrazolium salt assay technology.

• Targeting VEGFC-VEGFR-3 Axis in NASH-Related Liver Fibrosis

  2026-05-08

  This study elucidates how downregulation of the VEGFC-VEGFR-3 signaling axis, particularly through naringin administration or VEGFR-3 inhibition, attenuates hepatic fibrosis in NASH. The findings provide mechanistic insights into hepatocyte-macrophage interactions and highlight VEGFC as a promising therapeutic target for liver fibrosis.

• Evaluating Anti-Cancer Drug Responses: In Vitro Method Advan

  2026-05-07

  Schwartz's dissertation systematically dissects how in vitro assays distinguish between cell death and proliferative arrest when evaluating anti-cancer drugs. By clarifying the relationship between growth inhibition and cytotoxicity, the work advances rigor in preclinical drug evaluation and informs the use of targeted agents such as Serdemetan.

• Caspofungin in Antifungal Assays: Precision and Reliability

  2026-05-07

  This in-depth article guides biomedical researchers, lab technicians, and postgraduates through real-world experimental scenarios, illustrating how Caspofungin (SKU B4972) ensures reliable, reproducible results in antifungal research. By addressing experimental design, assay optimization, data interpretation, and product selection, it provides evidence-backed strategies for tackling Candida resistance and optimizing β-(1,3)-D-glucan biosynthesis pathway inhibition.

• Salinomycin: Polyether Ionophore Antibiotic in HCC Research

  2026-05-06

  Salinomycin is redefining hepatocellular carcinoma (HCC) research as a selective Wnt/β-catenin signaling pathway inhibitor and cancer cell apoptosis inducer. This article delivers hands-on workflow guidance, optimization strategies, and troubleshooting insights to maximize reproducibility and mechanistic clarity using APExBIO’s Salinomycin.

• Plant Exosome-Like Nanovesicles Reverse Testicular Injury vi

  2026-05-06

  This study demonstrates that exosome-like nanovesicles from Cistanche deserticola can alleviate cyclophosphamide-induced testicular injury by targeting cell cycle arrest in Sertoli cells. The findings provide mechanistic insight into miRNA-mediated regulation of P21 and suggest novel therapeutic strategies for male fertility preservation during chemotherapy.

• Chronic E-64 Cathepsin Inhibition in Salt-Sensitive Hyperten

  2026-05-05

  This study evaluated the effects of the irreversible cysteine cathepsin inhibitor E-64 on blood pressure and kidney injury in Dahl salt-sensitive rats. Despite effective cathepsin inhibition, E-64 treatment did not alter hypertension or renal damage, highlighting the nuanced role of cysteine proteases in salt-induced pathology and informing mechanistic research strategies.

• Aurora A Kinase Regulates Trained Immunity via SAM Metabolis

  2026-05-05

  Li et al. provide compelling evidence that Aurora A kinase (AurA) sustains trained immunity in innate immune cells through regulation of endogenous S-adenosylmethionine (SAM) metabolism and epigenetic chromatin states. This study identifies a methylation-dependent mechanism linking AurA activity to inflammatory gene accessibility and innate immune memory, revealing new intersections between cancer signaling, immunology, and metabolic control.

• Targeted Amikacin Delivery to Granulomas via Dendritic Cells

  2026-05-04

  This study pioneers the use of monocyte-derived dendritic cells (DCs) to deliver amikacin directly into granulomas in a murine model of Mycobacterium avium infection. The findings highlight a potential strategy for site-specific antibiotic delivery, reducing systemic toxicity while maintaining antimicrobial efficacy.

• Neuroinflammation Drives Mechanical Allodynia via CGRP/SP-Pi

  2026-05-04

  Liao et al. uncover a Ca2+-dependent neuroinflammatory mechanism linking trigeminal nerve compression to mechanical allodynia, mediated by co-activation of CGRP, SP, and Piezo2 in the trigeminal system. Their findings provide a mechanistic foundation for targeting peripheral sensitization pathways in trigeminal neuralgia research.

• Universal nPEC Method for Dual-Loaded Liposome Encapsulation

  2026-05-03

  This study by Tong Yuan et al. rigorously compares and validates methods for determining encapsulation efficiency in liposomes co-loaded with hydrophilic and lipophilic drugs. The nanoparticle exclusion chromatography (nPEC) method is identified as a universally accurate and efficient approach, streamlining dual-drug encapsulation analysis for advanced drug delivery research.

• PTX3 Counters Glucocorticoid-Induced ONFH via TLR4/NF-κB-FGF

  2026-05-02

  This study identifies pentraxin 3 (PTX3) as a protective factor against glucocorticoid-induced osteonecrosis of the femoral head (ONFH), operating through modulation of the TLR4/NF-κB/FGF21 signaling axis. The findings highlight a mechanistic link between innate immunity and bone preservation, offering a foundation for future therapeutic strategies targeting ER stress and bone loss.

• Demethyleneberberine: Mechanistic Power for Translational Im

  2026-05-02

  Demethyleneberberine (DMB), a natural isoquinoline alkaloid from Phellodendron bark, is redefining the translational research toolkit. By inhibiting NF-κB and MAPK signaling, DMB delivers robust anti-inflammatory, anti-fibrotic, neuroprotective, and anti-cancer effects validated across diverse preclinical models. This article synthesizes mechanistic depth, protocol precision, and strategic guidance to empower translational researchers seeking reproducibility and novel therapeutic insights. Drawing on peer-reviewed studies and workflow best practices, we explore how DMB advances disease modeling in autoimmune hepatitis, non-small cell lung cancer, and beyond—while providing actionable parameters and a critical perspective on clinical translation.

456 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page